Savara’s Molgramostim Shows Long-Term Efficacy in Rare Lung Disease Trial — Savara Inc.

Event summary

Savara’s Phase 3 IMPALA-2 trial data for molgramostim in autoimmune pulmonary alveolar proteinosis (aPAP) accepted for three presentations at ERS Congress 2026.
Oral and poster presentations highlight long-term efficacy, safety, and biomarker improvements in aPAP patients.
Bruce C. Trapnell, M.D., lead clinical investigator, emphasizes high retention rates and durability of effect through 48 weeks of open-label period.
Molgramostim is the first potential pharmacologic treatment for aPAP, a rare lung disease with no approved therapies.

The big picture

Savara’s molgramostim represents a potential breakthrough in treating autoimmune pulmonary alveolar proteinosis (aPAP), a rare and debilitating lung disease. The positive Phase 3 trial results position Savara as a leader in developing therapies for underserved respiratory conditions, though the company must navigate regulatory hurdles and commercialization challenges in a niche market. The broader biopharmaceutical industry is watching closely, as successful outcomes in rare diseases can drive significant value for developers.

What we're watching

Regulatory Pathway: Whether Savara can leverage these data to secure regulatory approval for molgramostim, given the lack of prior treatments for aPAP.
Commercialization Strategy: How Savara plans to position molgramostim in a niche market with limited prior therapeutic options.
Competitive Landscape: The pace at which other biopharmaceutical companies may enter the aPAP space, given the positive trial results.